Fulcrum Therapeutics move lower ‘overdone,’ says Stifel

TipRanks

Thu, February 26, 2026 at 12:27 AM GMT+9 1 min read

In this article:

FULC

+4.14%

Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF may comfortably be greater than 20% given the strength of the initial cut at ASH, the firm thinks “overly nitpicking 19.3% is splitting hairs and misses the bigger picture” as these data surpassed the physician “bar” and that pociredir is reaching HbF levels expected to be highly protective of disease. Even with a rebound this morning, shares significantly discount a soon-to-be late-stage asset with a validated mechanism of action in the white-space sickle cell disease market, argues the analyst, who has a Buy rating and $25 price target on Fulcrum shares.

Claim 50% Off TipRanks Premium

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on FULC:

Disclaimer & DisclosureReport an Issue

Truist remain buyers of Fulcrum Therapeutics shares on weakness

Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir

Fulcrum Therapeutics reports Q4 EPS (31c), consensus (30c)

Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet

Pociredir’s Emerging Strength in Sickle Cell Disease Positions FULC for Upside Ahead of 1Q26 Data

Terms and Privacy Policy

Privacy Dashboard

More Info